FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria

Biotech Alexion has issued a press release announcing that FDA has approved, two months earlier than scheduled, its ALXN1210 therapy for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare condition. The drug will be marketed as Ultomiris, the company has added.